<DOC>
	<DOCNO>NCT03022448</DOCNO>
	<brief_summary>The aim non-interventional study prospectively collect analyze data geriatric assessment patient undergo systemic 1st line therapy trabectedin focus patient assess treat physician unsuited receive standard chemotherapy anthracyclines / ifosfamide . Trabectedin use accord local SmPC . Modification treatment schedule follow standard medical practice discretion treat physician part Observational Plan .</brief_summary>
	<brief_title>Geriatric Assessmen Elderly `` Unsuited '' Patients Receiving Trabectedin First Line Treatment For Advanced Soft Tissue Sarcomas ( STS )</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Written inform consent Age ≥ 60 year study inclusion limit number `` unsuited '' patient young 60 year Histologically proven advanced and/or metastatic STS , intermediate/high grade Presence measurable disease accord RECIST 1.1 . ( optional , accord local clinical practice ) Patients indicate 1st line treatment trabectedin accord local SmPC ECOG Performance Status 0 , 1 2 bone marrow function accord local SmPC hepatic function accord local SmPC Ability understand follow studyrelated instruction Histologically proven advance and/or metastatic STS follow tumor type : Embryonal rhabdomyosarcoma Chondrosarcoma ( exclude extraskeletal myxoid chondrosarcoma ) Osteosarcoma ( exclude extraskeletal osteosarcoma ) Ewing tumors/primitive neuroectodermal tumor Gastrointestinal stromal tumor Dermatofibrosarcoma protuberans Use investigational agent within 28 day prior treatment start Exclusion period study simultaneous participation clinical study Contraindications accord local SmPC Yondelis® ( see Appendix A ) Subject custody order authority court law Previous assignment ETrab study ( An individual subject may include study ) Criteria opinion investigator preclude participation scientific reason , reason compliance , reason subject 's safety</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>soft tissue sarcoma ( STS )</keyword>
	<keyword>trabectedin</keyword>
	<keyword>metastatic STS patient</keyword>
	<keyword>overall survival</keyword>
</DOC>